BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 11264179)

  • 1. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia.
    Chen JS; Coustan-Smith E; Suzuki T; Neale GA; Mihara K; Pui CH; Campana D
    Blood; 2001 Apr; 97(7):2115-20. PubMed ID: 11264179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
    Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
    Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
    Burnusuzov HA; Spasova MI; Murdjeva MA; Stoyanova AA; Mumdziev IN; Kaleva VI; Belcheva MI; Bosheva MN
    Folia Med (Plovdiv); 2016 Mar; 58(1):28-35. PubMed ID: 27383875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
    Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
    Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia.
    Tsitsikov E; Harris MH; Silverman LB; Sallan SE; Weinberg OK
    Int J Lab Hematol; 2018 Jun; 40(3):343-351. PubMed ID: 29500862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Easy discrimination of hematogones from lymphoblasts in B-cell progenitor acute lymphoblastic leukemia patients using CD81/CD58 expression ratio.
    Nagant C; Casula D; Janssens A; Nguyen VTP; Cantinieaux B
    Int J Lab Hematol; 2018 Dec; 40(6):734-739. PubMed ID: 30113764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High frequency of heat shock protein 27 overexpression is a highly effective, high-coverage marker for minimal residual disease detection in children with B-cell acute lymphoblastic leukemia.
    Chou SW; Su YH; Lu MY; Chang HH; Yang YL; Lin DT; Lin KH; Coustan-Smith E; Jou ST
    Pediatr Blood Cancer; 2023 Jan; 70(1):e29990. PubMed ID: 36250996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.
    Baraka A; Sherief LM; Kamal NM; Shorbagy SE
    Int J Hematol; 2017 Jun; 105(6):784-791. PubMed ID: 28324281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttherapy surveillance of B-cell precursor acute lymphoblastic leukemia. Value of polymerase chain reaction and limitations of flow cytometry.
    Kallakury BV; Hartmann DP; Cossman J; Gootenberg JE; Bagg A
    Am J Clin Pathol; 1999 Jun; 111(6):759-66. PubMed ID: 10361511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia.
    Rzepiel A; Kutszegi N; Gézsi A; Sági JC; Egyed B; Péter G; Butz H; Nyírő G; Müller J; Kovács GT; Szalai C; Semsei ÁF; Erdélyi DJ
    J Transl Med; 2019 Nov; 17(1):372. PubMed ID: 31727091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome.
    Gruhn B; Hongeng S; Yi H; Hancock ML; Rubnitz JE; Neale GA; Kitchingman GR
    Leukemia; 1998 May; 12(5):675-81. PubMed ID: 9593264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of CD58 in childhood B-lineage acute lymphoblastic leukemia and its feasibility in minimal residual disease detection].
    Li YF; Zhao XM; Sheng GY; Yue BH; Luo Y
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Aug; 17(8):825-9. PubMed ID: 26287347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
    Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Application of effective antigen combinations in childhood B lineage acute lymphoblastic leukemia].
    Liu Y; Tang JY; Xu C; Gu LJ; Xue HL; Chen J; Pan C; Dong L; Zhou M
    Zhonghua Er Ke Za Zhi; 2009 May; 47(5):366-70. PubMed ID: 19573409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precursor B-cell lymphoblastic lymphoma: a predominantly extranodal tumor with low propensity for leukemic involvement.
    Lin P; Jones D; Dorfman DM; Medeiros LJ
    Am J Surg Pathol; 2000 Nov; 24(11):1480-90. PubMed ID: 11075849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia.
    Coustan-Smith E; Kitanaka A; Pui CH; McNinch L; Evans WE; Raimondi SC; Behm FG; Aricò M; Campana D
    Blood; 1996 Feb; 87(3):1140-6. PubMed ID: 8562940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WT1 protein expression in childhood acute leukemia.
    Kerst G; Bergold N; Gieseke F; Coustan-Smith E; Lang P; Kalinova M; Handgretinger R; Trka J; Müller I
    Am J Hematol; 2008 May; 83(5):382-6. PubMed ID: 18161786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation.
    Uckun FM; Herman-Hatten K; Crotty ML; Sensel MG; Sather HN; Tuel-Ahlgren L; Sarquis MB; Bostrom B; Nachman JB; Steinherz PG; Gaynon PS; Heerema N
    Blood; 1998 Aug; 92(3):810-21. PubMed ID: 9680349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia.
    Neale GA; Coustan-Smith E; Pan Q; Chen X; Gruhn B; Stow P; Behm FG; Pui CH; Campana D
    Leukemia; 1999 Aug; 13(8):1221-6. PubMed ID: 10450750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key Markers of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.
    Xia M; Zhang H; Lu Z; Gao Y; Liao X; Li H
    J Pediatr Hematol Oncol; 2016 Aug; 38(6):418-22. PubMed ID: 27438018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.